The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer

作者：Lei Liu, Fuxia Li, Jing Zhao, Xiaoli Zhuo, Jingjiang Lai, Jingliang Wang, Feng-Xian Jiang, Wei Xu, Fang Luan, Xiaoyan Lin, Shuping Yang, Guobin Fu · 发表于：Journal of Cancer · 年份：2023 · DOI：10.7150/jca.77199 · 被引用次数：16 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Cancer Genomics and Diagnostics

In the real world, patients with KRAS mutations benefit from first-line immunotherapy, immune-combination modalities are more effective, and immune efficacy is positively correlated with PD-L1 expression; Patients with other driver mutations (BRAF, NRAS, Her2, MET, ROS1) benefit similarly to mutation-negative patients in first-line immunotherapy, and immunotherapy is recommended for first-line therapy; Immunotherapy is worse effective in patients with EGFR mutations, immunotherapy is not recommended in first-line therapy even patients with high PD-L1 expression.